BPC-157: Mechanism, Literature, and Handling
Last updated 2026-07-19
BPC-157 is a synthetic pentadecapeptide corresponding to residues 1-15 of body protection compound, a protein isolated from human gastric juice. It is among the most widely discussed and least rigorously replicated peptides in the repair literature — a combination that makes an honest reference page unusually valuable.
Structure and stability
The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of 1419.53 g/mol and no cysteine residues, meaning no disulfide bridging and no associated oxidative instability during handling.
Its most-cited physical property is stability in human gastric juice — reported stable for more than 24 hours, where most peptides of comparable size degrade within minutes. This is why a substantial fraction of the animal literature uses oral administration, which is unusual for a peptide of this class and is the property that drove early interest.
The high proline content (four residues, three consecutive) constrains backbone flexibility and is the most likely structural contributor to protease resistance.
Proposed mechanisms
The angiogenic pathway is the best-supported. Multiple studies report upregulation of VEGFR2 expression and downstream activation of the VEGFR2-Akt-eNOS signaling axis in endothelial cells, with corresponding increases in tube formation in vitro.
A second line of work implicates the nitric oxide system. BPC-157 has been reported to counteract the effects of both NO synthase inhibition (L-NAME) and NO donation (L-arginine) in rodent models, which has been interpreted as a modulatory rather than purely agonist or antagonist relationship.
A third strand concerns the FAK-paxillin pathway in tendon fibroblast studies, where increased cell migration and survival have been reported in culture.
State of the evidence
This is where a researcher's judgment matters most, and where most supplier pages go quiet. The overwhelming majority of published BPC-157 work originates from a single research group in Zagreb, led by Predrag Sikiric. That group has produced a large and internally consistent body of work across many injury models.
Independent replication outside that group is limited. This does not make the findings wrong — single-group dominance is common in early-stage research on compounds without commercial sponsorship — but it does mean the effect sizes and breadth of activity reported should be treated as provisional rather than established.
There is no published human clinical trial data of the kind that would support efficacy claims of any sort. Research designs should be powered and controlled accordingly, and comparisons against an independent replication where one exists are more informative than another single-group citation.
Laboratory handling
Lyophilized BPC-157 is stable at -20°C protected from light for extended periods. Reconstituted solution should be held at 2-8°C and used within approximately 30 days.
Reconstitute by directing bacteriostatic water slowly down the interior vial wall rather than onto the powder directly. Swirl gently until dissolved; never shake or vortex, as mechanical agitation at the air-liquid interface denatures peptides and is a common source of unexplained potency loss between aliquots.
Repeated freeze-thaw cycling of reconstituted material degrades peptide integrity. Aliquot into single-use volumes at first reconstitution if the protocol spans multiple sessions.
Evidence assessment
Evidence base: substantial volume, narrow provenance. Weight accordingly and prefer independently replicated findings where they exist.
Published literature
222 papers indexed on PubMed for BPC-157. Showing 12, reviews first.
- 01Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK et al. · Am J Sports Med · 2026
- 02Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF et al. · J Am Acad Orthop Surg Glob Res Rev · 2026
- 03Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review
Józwiak M et al. · Pharmaceuticals (Basel) · 2025
- 04Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Vasireddi N et al. · HSS J · 2025
- 05Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
McGuire FP et al. · Curr Rev Musculoskelet Med · 2025
- 06Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?
DeFoor MT, Dekker TJ · Arthroscopy · 2025
- 07The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity
Sikiric P et al. · Pharmaceuticals (Basel) · 2024
- 08Pentadecapeptide BPC 157 and the central nervous system
Vukojevic J et al. · Neural Regen Res · 2022
- 09Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
Seiwerth S et al. · Front Pharmacol · 2021
- 10Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Gwyer D et al. · Cell Tissue Res · 2019
- 11Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Lee E, Padgett B · Altern Ther Health Med · 2021
- 12The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Chang CH et al. · J Appl Physiol (1985) · 2011
Indexed from PubMed on 2026-07-19. Citations link to the source; we do not reproduce abstracts.
All products are intended strictly for laboratory research use. Not for human or veterinary use. Not for diagnostic or therapeutic use. Not a drug, food, or cosmetic.